Elevated platelet vesicular monoamine transporter density in untreated patients diagnosed with major depression

Michal Zucker, Alex Aviv, Assaf Shelef, Abraham Weizman, Moshe Rehavi*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The intraneuronal uptake of monoamines into brain synaptic vesicles is mediated by the vesicular monoamine transporter (VMAT2). This transporter plays a major role in monoamine storage and quantal release. Recently we demonstrated a high degree of similarity between the pharmacodynamic characteristics of platelet and brain VMAT2. In the present study we measured the VMAT2 density, using [3H]dihydrotetrabenazine ([3H]TBZOH) as a ligand, in platelets of untreated patients diagnosed with major depressive disorder (MDD) (n=10; three with recurrent depression and seven with first episode depression) compared to sex- and age-matched healthy control subjects (n=23). A significant elevation in the VMAT2 density (Bmax) was observed in the platelets of untreated MDD patients (+24%) compared to healthy control subjects. No significant change was found in the affinity constant (Kd). The increased platelet VMAT2 density may reflect depression-related enhancement of the capacity to accumulate monoamines in the vesicles in the presence of lower monoamine turnover.

Original languageEnglish
Pages (from-to)251-256
Number of pages6
JournalPsychiatry Research
Volume112
Issue number3
DOIs
StatePublished - 15 Nov 2002

Keywords

  • Depression
  • Platelet
  • Vesicular monoamine transporter
  • [H]dihydrotetrabenazine

Fingerprint

Dive into the research topics of 'Elevated platelet vesicular monoamine transporter density in untreated patients diagnosed with major depression'. Together they form a unique fingerprint.

Cite this